Not all biomarkers of human NASH were robustly altered by the cues, e.g. PARP1 overexpression was observed with fat loading, but a subsequent reduction in SIRT1 expression, matching clinical data56 was not observed. The gene discussed is PARP1; the disease is metabolic dysfunction-associated steatohepatitis.